Condition: Juvenile Myoclonic Epilepsy · Sponsor: Jazz Pharmaceuticals
This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@JazzPharma.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | New Haven, Connecticut, United States | — |
| Clinical Trial Site | Tampa, Florida, United States | — |
| Clinical Trial Site | Atlanta, Georgia, United States | — |
| Clinical Trial Site | Savannah, Georgia, United States | — |
| Clinical Trial Site | Honolulu, Hawaii, United States | — |
| Clinical Trial Site | Hawthorne, New York, United States | — |
| Clinical Trial Site | Cincinnati, Ohio, United States | — |
| Clinical Trial Site | Portland, Oregon, United States | — |
| Clinical Trial Site | Roanoke, Virginia, United States | — |
| Clinical Trial Site | Winchester, Virginia, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07723963